Evidence map›Paper›PMID 39236011›Full record

ArticlePLOS digital health2024

Optimizing COVID-19 testing resources use with wearable sensors.

Giorgio Quer, Arinbjörn Kolbeinsson, Jennifer M Radin, Luca Foschini, Jay Pandit

Abstract read
In one paragraph

Article in PLOS digital health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Giorgio QuerScripps Research Translational Institute, La Jolla, California, United States of America.ORCID https://orcid.org/0000-0003-2208-7912
Arinbjörn KolbeinssonUniversity of Virginia, Charlottesville, Virginia, United States of America.
Jennifer M RadinScripps Research Translational Institute, La Jolla, California, United States of America.
Luca FoschiniSage Bionetworks, Seattle, Washington, United States of America.
Jay PanditScripps Research Translational Institute, La Jolla, California, United States of America.

Funding

Scripps Translational Science InstituteUL1TR002550 · NCATS · SCRIPPS RESEARCH INSTITUTE, THE · PI TOPOL, ERIC JEFFREY · 2018 to 2022
$28.9M
Scripps Clinical and Translational Science HubUM1TR004407 · NCATS · SCRIPPS RESEARCH INSTITUTE, THE · PI Eric Jeffrey Topol · 2023 to 2026
$24.2M
NCATS NIH HHS UL1 TR002550NCATS NIH HHS UM1 TR004407
6 · The paper itself

Abstract

The timely identification of infectious pre-symptomatic and asymptomatic cases is key towards preventing the spread of a viral illness like COVID-19. Early identification has been done through routine testing programs, which are indeed costly and potentially burdensome for individuals who should be tested with high frequency. A supplemental tool is represented by wearable technology, that can passively monitor and identify individuals at high risk, alerting them to take a test. We designed a Markov chain model and simulated a routine testing and a wearable testing strategy to estimate the number of tests required and the average number of days in which an individual is infectious and undetected. According to our model, with 2 test per month available, we have that the number of infectious and undetected days is 4.1 in the case of routine testing, while it decreases by 46% and 27% with a wearable testing strategy in the presence or absence of self-reported symptoms. The proposed parametric model can be used for different viral illnesses by tuning its parameters. It shows that wearable technology informing a testing strategy can significantly reduce the number of infectious days in which an individuals can spread the virus. With the same number of infectious days, by using wearables we can potentially reduce the number of required tests and the cost of the testing strategy.

Identifiers

PMID39236011
PMCPMC11376555

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.